skip to Main Content
himagine Solutions is now a part of Omega Healthcare. Click here to learn more.

Tumor Tip of the Week-Xgeva

Scenario: 2021 patient presents with metastatic prostate adenocarcinoma to the bones, receiving Xgeva. Question:  Would you code the Xgeva to Hormone therapy? Yes No Answer:   No Rationale: SEER*Rx Interactive Antineoplastic Drugs Database https://seer.cancer.gov/seertools/seerrx/ Xgeva Category Ancillary Agent Biologic therapy (BRM, immunotherapy) Subcategory PLEASE SEE IMPORTANT CODING INFORMATION IN REMARKS FIELD…

Read More

Tumor Tip of the Week-SEER Appendix C Coding Guidelines

Scenario: 2021 TURBT: Low Grade Urothelial Carcinoma (No other information available) Question:  What is the correct behavior? /2 in situ /3 invasive Answer:   /2 in situ Rationale: SEER Appendix C 2021 Coding Guidelines Bladder page 5 https://seer.cancer.gov/manuals/2021/appendixc.html Code the behavior as in situ (/2) when • The…

Read More

Coding Webinar-May 2021

Join the himagine compliance team as we provide an overview of various lower leg fractures and types of repairs in the outpatient setting. We will highlight various types of fractures, corresponding ICD10-CM diagnosis codes, CPT procedural codes and review multiple…

Read More

Tumor Tip of the Week-Is this reportable?

Scenario: A. 05-28-2021 patient diagnosed with Thymoma, NOS B. 05-28-2021 patient diagnosed with GIST, NOS C. 05-28-2021 patient diagnosed with early evolving melanoma Question:  Which of the above scenarios are reportable? [Check all that apply.] A B C Answer:   A, B, C…

Read More

Tumor Talk-Breast Cancer 2

Join us to discuss some of the nuances cancer registrars face abstracting various case scenarios. We will identify various resources available to the registrar and how to apply that knowledge when abstracting. CEU certificates will no longer be provided for…

Read More
Back To Top
×Close search
Search
Send this to a friend